
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is poised for positive growth as they navigate through various risks, with promising Phase II trial results supported by positive recommendations from an independent Data and Safety Monitoring Board. In addition, upcoming milestones and potential strategic clarity at the shareholders meeting in April could provide value drivers for the company's pipeline of CD19 and CD22-targeted ARTEMIS T-cell therapies. While the company's financials and future cash burn may require future raises, the potential for breakthrough treatments in blood cancers and solid tumors make Estrella Immunopharma an attractive stock for investors with a long-term outlook.
Bears say
Estrella Immunopharma is facing significant challenges for its blood cancer and solid tumor treatments, with declines in patient populations and potential dilution from recent capital raisings. Despite management's efforts to expand its pipeline and operations, the company's financials do not support a positive outlook for the stock's continued decline in value due to these prolonged challenges.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares